> 首页 > 产品 > 一抗 > 其他 > Anti-BAFF & IL-17A Reference Antibody (Tibulizumab)

Anti-BAFF & IL-17A Reference Antibody (Tibulizumab)

Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 92.06%, determined by SEC-HPLC.
Tibulizumab bound to BAFF protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Tibulizumab bound hu-BAFF-Fc, and the EC50 was 0.081 nM.
Tibulizumab bound to IL-17a protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Tibulizumab bound to in hu-IL-17a-His, and the EC50 was 0.128 nM.
Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Tibulizumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Tibulizumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 3.81 nM.
The detected molecular weight of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 201.34 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9Y275 & Q16552
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information
Target/Specificity	TNFSF13B / BAFF / CD257,IL-17 / IL-17A / CTLA-8
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.